Drs. Jamil Asselah and Kim Ma return to discuss the latest ASCO 2025 data, focusing on SERENA-6 PFS outcomes and DESTINY-Breast09, where T-DXd plus pertuzumab sets a new first-line standard in HER2+ mBC with practice-changing impact.
10:08
0
